CD4 and cerebral small vessel disease: Since the cohort of PWH we enrolled was relatively young (average age 34 years) with preserved immune function before starting cART (average nadir and baseline CD4+ cell count > 400 cell/uL), it could be envisioned that PWH as they age would be further exposed to CBVD and in particular to cerebral small vessel disease (CSVD).